Therapeutic Expertise

Cell and Gene Therapy

Support seamless execution of CGT clinical development.

Flexible End-To-End Engagement Models and Customized Approaches


In terms of industry resources, Tigermed CGT Solution has a team of top experts, 100+ KOL resources, more than 200 professional CGT strategic cooperation centers, as well as a number of cooperative GCP centers and scientific research institutions, integrating advantageous resources to serve CGT customers.

In addition, relying on the integrated R&D service platform for innovative drugs, Tigermed's professional CGT solutions can provide integrated and specialized services ranging from preclinical super-cell donor library screening services, CMC, pharmacodynamic modeling exploration, pharmacology and toxicology, GLP safety assessment center, registration, medicine, operation, numerical statistics, PV, MM, SMO, CGT special testing project center laboratory, etc., and provide customized services for R&D institutions according to their needs. We can also provide R&D institutions with customized and consultative project strategy planning and other professional services according to their needs, so as to accelerate the clinical development and marketing process of CGT products in an efficient and high-quality way.

CGT Clinical Development

Focus on CGT solutions provide integrated services from preclinical super cell donor bank screening, to pharmacodynamic and toxicological studies, to registration filing and clinical trials, and provide consultative project formulation strategy planning and specific professional support for CGT therapeutic areas.

CGT clinical studies
87+
Stem cells clinical studies
20+
Gene therapy clinical studies
60+

Benefits Your CGT Product Development Life Cycle

Providing customized and insightful study designs

New drug types / New mechanisms of action / Existence of faster-moving analogs...

Identifying product value, market access and positioning

Assessment of clinical value, market positioning and potential differentiation based on unique mechanisms of the drug type, characteristics of the target indications

Evaluating the possibility of exceeding study timelines

Formulate competitive and differentiated development strategies and assess the feasibility of accelerated approval, dual reporting in China and abroad, and international multi-center clinical designs

Estimating the risks of amendment and delays

Managing Complexity in Clinical Implementation /
Difficult Identification and Response /
Assessment of the likelihood of poor efficacy /
Assessment of Insufficient Evidence of Safety /
...

Improving your protocols with up-to-date market and regulatory intelligence

Adapt clinical development strategies and trial protocols according to the latest regulatory requirements and competitive developments

Clinical Trials Delivered by Indications

Multiple Myeloma

Periodontitis

Leukaemia

Hepatocellular
Carcinoma

Lymphoma

Crohn's Disease

Hematologic Malignancies

Rare Disease

Solid Tumor

Sequela of Apoplexy

Parkinson’s Disease

NSCLC

COPD

ARDS

Hemophilia

Thalassemia

Coronary Heart Disease

Ulcerative Colitis

Autoimmune Disease

Pneumonia

Gastric Carcinoma

GVHD

Osteoarthritis

Ophthalmology

Let's Connect for a Conversation